ABCL - AbCellera Incyte partner for antibody-based cancer drugs
2023-09-13 10:25:54 ET
More on AbCellera, Incyte, etc.
- AbCellera Biologics Inc. ( ABCL ) Q2 2023 Earnings Call Transcript
- AbCellera Biologics Inc. 2023 Q2 - Results - Earnings Call Presentation
- Incyte Corporation ( INCY ) Q2 2023 Earnings Call Transcript
- AbCellera Biologics: Promising Platform, But Watch-And-Wait Approach Advised
- Opzelura's Growth Challenges: Incyte Faces Hurdles In Nonsegmental Vitiligo Market
- Incyte a new buy at Citi on Opzelura performance
- Why did AbCellera Biologics stock dip today? AI-driven rally cools
- Incyte wins U.K. approval for vitiligo cream Opzelura
For further details see:
AbCellera, Incyte partner for antibody-based cancer drugs